First Step With Singulair® Therapy (0476-323) (FIRST)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
Condition or disease
Drug: MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 WeeksDrug: Comparator: Fluticasone / Duration of Treatment: 6 Weeks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
First time diagnosis of mild asthma symptoms which requires an antiinflammatory controller medication
Patients not controlled with short acting beta2 agonist (sab) therapy (requiring more than one treatment per week but less than 7 per week)
Patients dissatisfied with low dose ics therapy, or patients reluctant to take ics therapy, or patients insufficiently controlled due to non-compliance with low dose ics therapy through out the preceding 6 weeks
Patient's forced expiratory volume in one second (fev1) is < 80% of predicted value
Patient on combination therapy
Patient on long acting beta2 agonists
Patient on using moderate to high doses of ICS. (ICS >250 µ g/day flovent® or equivalent per day)